{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T00:09:31Z","timestamp":1793578171244,"version":"4.5.0"},"reference-count":36,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T00:00:00Z","timestamp":1751414400000},"content-version":"vor","delay-in-days":2,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100008750","name":"Shanghai Hospital Development Center","doi-asserted-by":"publisher","award":["SHDC22024317"],"award-info":[{"award-number":["SHDC22024317"]}],"id":[{"id":"10.13039\/501100008750","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008750","name":"Shanghai Hospital Development Center","doi-asserted-by":"publisher","award":["GWVI-9"],"award-info":[{"award-number":["GWVI-9"]}],"id":[{"id":"10.13039\/501100008750","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003399","name":"Science and Technology Commission of Shanghai Municipality","doi-asserted-by":"publisher","award":["ZD2021CY001"],"award-info":[{"award-number":["ZD2021CY001"]}],"id":[{"id":"10.13039\/501100003399","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,6,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>We aimed to investigate the prevalence of liver fibrosis and identify the associated risk factors among people with HIV (PWH) and metabolic dysfunction\u2013associated steatotic liver disease (MASLD).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Abdominal ultrasonography and transient elastography were performed to assess liver fibrosis and steatosis. Lean MASLD was defined as MASLD occurring in PWH with a body mass index (BMI) &amp;lt; 24\u2005kg\/m2. A cutoff of liver stiffness measurement \u2265 7.1\u2005kPa was set for significant liver fibrosis. The prevalence, correlation factors, and risk factors were evaluated.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Among 361 PWH, 250 (69.25%) had a BMI &amp;lt; 24\u2005kg\/m2, and 141 (39.06%) were diagnosed with MASLD. The 141 PWH with MASLD were classified as 2 groups based on BMI: 58 (41.13%) as lean MASLD and 83 (58.87%) as overweight MASLD. Significant fibrosis was observed in 121 of the 361 PWH, including 75 of the 141 with MASLD, 28 of the 58 with lean MASLD, and 47 of the 83 with overweight MASLD. Among PWH with MASLD, independent risk factors for significant liver fibrosis included higher alanine aminotransferase levels and the presence of type 2 diabetes. Among PWH with lean MASLD, independent risk factors for significant liver fibrosis included elevated aspartate aminotransferase levels and the administration of non-nucleoside reverse transcriptase inhibitors.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Significant liver fibrosis is highly prevalent among PWH and MASLD. Multiple risk factors are associated with significant liver fibrosis among PWH. These findings underscore the importance of early identification and management of liver fibrosis in PWH.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Clinical Trials Registration<\/jats:title>\n                  <jats:p>NCT04215926.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ofid\/ofaf369","type":"journal-article","created":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T08:01:46Z","timestamp":1751443306000},"source":"Crossref","is-referenced-by-count":5,"title":["Prevalence and Risk Factors of Liver Fibrosis Among People With HIV and Metabolic Dysfunction\u2013Associated Steatotic Liver Disease"],"prefix":"10.1093","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7849-5072","authenticated-orcid":false,"given":"Wei","family":"Xu","sequence":"first","affiliation":[{"name":"Department of Infection and Immunity, Shanghai Public Health Clinical Center, Fudan University , Shanghai ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danping","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Infection and Immunity, Shanghai Public Health Clinical Center, Fudan University , Shanghai ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renfang","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Infection and Immunity, Shanghai Public Health Clinical Center, Fudan University , Shanghai ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3850-4875","authenticated-orcid":false,"given":"Jun","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Infection and Immunity, Shanghai Public Health Clinical Center, Fudan University , Shanghai ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinzhong","family":"Shen","sequence":"additional","affiliation":[{"name":"Department of Infection and Immunity, Shanghai Public Health Clinical Center, Fudan University , Shanghai ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,7,2]]},"reference":[{"key":"2025071504015707900_ofaf369-B1","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s12072-024-10774-3","article-title":"The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic dysfunction\u2013associated fatty liver disease","volume":"19","author":"Eslam","year":"2025","journal-title":"Hepatol Int"},{"key":"2025071504015707900_ofaf369-B2","first-page":"87","article-title":"HIV and liver disease","volume":"25","author":"Navarro","year":"2022","journal-title":"AIDS Rev"},{"key":"2025071504015707900_ofaf369-B3","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","article-title":"EASL-EASD-EASO clinical practice guidelines on the management of metabolic dysfunction associated steatotic liver disease (MASLD)","volume":"81","author":"European Association for the Study of the Liver, European Association for the Study of Diabetes, European Association for the Study of Obesity","year":"2024","journal-title":"J Hepatol"},{"key":"2025071504015707900_ofaf369-B4","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1053\/j.gastro.2019.11.312","article-title":"MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease","volume":"158","author":"Eslam","year":"2020","journal-title":"Gastroenterology"},{"key":"2025071504015707900_ofaf369-B5","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1016\/j.jhep.2023.06.003","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"79","author":"Rinella","year":"2023","journal-title":"J Hepatol"},{"key":"2025071504015707900_ofaf369-B6","first-page":"955","article-title":"Guideline for the prevention and treatment of metabolic dysfunction\u2013associated fatty liver disease (version 2024)","volume":"12","author":"Fan","year":"2024","journal-title":"J Clin Transl Hepatol"},{"key":"2025071504015707900_ofaf369-B7","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1097\/HEP.0000000000000670","article-title":"Metabolic dysfunction\u2013associated steatotic liver disease: update and impact of new nomenclature on the American Association for the Study of Liver Diseases practice guidance on nonalcoholic fatty liver disease","volume":"79","author":"Kanwal","year":"2024","journal-title":"Hepatology"},{"key":"2025071504015707900_ofaf369-B8","doi-asserted-by":"crossref","first-page":"9158","DOI":"10.1038\/s41598-023-32965-y","article-title":"Metabolic dysfunction\u2013associated fatty liver disease in people living with HIV","volume":"13","author":"Michel","year":"2023","journal-title":"Sci Rep"},{"key":"2025071504015707900_ofaf369-B9","first-page":"1035","article-title":"High prevalence of nonalcoholic fatty liver disease in HIV-infected patients: a systematic review and meta-analysis","volume":"66","author":"Maurice","year":"2017","journal-title":"J Hepatol"},{"key":"2025071504015707900_ofaf369-B10","first-page":"502","article-title":"Nonalcoholic fatty liver disease in lean\/nonobese and obese individuals: a comprehensive review on prevalence, pathogenesis, clinical outcomes, and treatment","volume":"11","author":"Patel","year":"2023","journal-title":"J Clin Transl Hepatol"},{"key":"2025071504015707900_ofaf369-B11","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1111\/hiv.13017","article-title":"Association of body mass index with immune recovery, virological failure and cardiovascular disease risk among people living with HIV","volume":"22","author":"Han","year":"2021","journal-title":"HIV Med"},{"key":"2025071504015707900_ofaf369-B12","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1097\/COH.0000000000000706","article-title":"Hepatotoxicity of contemporary antiretroviral drugs","volume":"16","author":"Rivera","year":"2021","journal-title":"Curr Opin HIV AIDS"},{"key":"2025071504015707900_ofaf369-B13","doi-asserted-by":"crossref","first-page":"e000166","DOI":"10.1136\/bmjgast-2017-000166","article-title":"Mechanisms of liver disease in patients infected with HIV","volume":"4","author":"Kaspar","year":"2017","journal-title":"BMJ Open Gastroenterol"},{"key":"2025071504015707900_ofaf369-B14","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s11904-020-00531-0","article-title":"NASH in HIV","volume":"17","author":"Cervo","year":"2020","journal-title":"Curr HIV\/AIDS Rep"},{"key":"2025071504015707900_ofaf369-B15","doi-asserted-by":"crossref","first-page":"e86","DOI":"10.1097\/QAI.0000000000001936","article-title":"Diagnostic accuracy of noninvasive markers of steatosis, NASH, and liver fibrosis in HIV-monoinfected individuals at risk of nonalcoholic fatty liver disease (NAFLD): results from the ECHAM study","volume":"80","author":"Lemoine","year":"2019","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2025071504015707900_ofaf369-B16","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.jhep.2016.12.022","article-title":"Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis","volume":"66","author":"Karlas","year":"2017","journal-title":"J Hepatol"},{"key":"2025071504015707900_ofaf369-B17","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/S2468-1253(19)30383-8","article-title":"FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study","volume":"5","author":"Newsome","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2025071504015707900_ofaf369-B18","first-page":"1187","article-title":"Performance of the FAST score in global NASH trials: a meta-analysis","volume":"75","author":"Newsome","year":"2021","journal-title":"J Hepatol"},{"key":"2025071504015707900_ofaf369-B19","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.immuni.2013.10.001","article-title":"Systemic effects of inflammation on health during chronic HIV infection","volume":"39","author":"Deeks","year":"2013","journal-title":"Immunity"},{"key":"2025071504015707900_ofaf369-B20","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.3390\/cells10051263","article-title":"Hepatotoxicity of contemporary antiretroviral drugs: a review and evaluation of published clinical data","volume":"10","author":"Otto","year":"2021","journal-title":"Cells"},{"key":"2025071504015707900_ofaf369-B21","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1002\/hep.29085","article-title":"Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta-analysis","volume":"65","author":"Dulai","year":"2017","journal-title":"Hepatology"},{"key":"2025071504015707900_ofaf369-B22","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1111\/liv.15323","article-title":"Prevalence estimation of significant fibrosis because of NASH in Spain combining transient elastography and histology","volume":"42","author":"Calleja","year":"2022","journal-title":"Liver Int"},{"key":"2025071504015707900_ofaf369-B23","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1097\/QAD.0000000000003312","article-title":"Prevalence and risk factors of nonalcoholic steatohepatitis with significant fibrosis in people with HIV","volume":"36","author":"Michel","year":"2022","journal-title":"AIDS"},{"key":"2025071504015707900_ofaf369-B24","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1093\/cid\/ciad203","article-title":"FibroScan\u2013aspartate aminotransferase score predicts liver-related outcomes, but not extrahepatic events, in a multicenter cohort of people with human immunodeficiency virus","volume":"77","author":"Sebastiani","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2025071504015707900_ofaf369-B25","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1002\/oby.23263","article-title":"Type 2 diabetes mellitus increases the risk of hepatic fibrosis in individuals with obesity and nonalcoholic fatty liver disease","volume":"29","author":"Barb","year":"2021","journal-title":"Obesity (Silver Spring)"},{"key":"2025071504015707900_ofaf369-B26","first-page":"663","article-title":"The significance of differences in fatty acid metabolism between obese and non-obese patients with non-alcoholic fatty liver disease","volume":"22","author":"Nakamuta","year":"2008","journal-title":"Int J Mol Med"},{"key":"2025071504015707900_ofaf369-B27","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1111\/jgh.16049","article-title":"Epidemiology and prevalence of lean nonalcoholic fatty liver disease and associated cirrhosis, hepatocellular carcinoma, and cardiovascular outcomes in the United States: a population-based study and review of literature","volume":"38","author":"Almomani","year":"2023","journal-title":"J Gastroenterol Hepatol"},{"key":"2025071504015707900_ofaf369-B28","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1111\/hiv.13274","article-title":"Dangerous liaisons: NAFLD and liver fibrosis increase cardiovascular risk in HIV","volume":"23","author":"Cervo","year":"2022","journal-title":"HIV Med"},{"key":"2025071504015707900_ofaf369-B29","doi-asserted-by":"crossref","first-page":"1217249","DOI":"10.3389\/fendo.2023.1217249","article-title":"Lean nonalcoholic fatty liver disease and sarcopenia","volume":"14","author":"Chen","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2025071504015707900_ofaf369-B30","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s11904-024-00708-x","article-title":"Metabolic complications associated with use of integrase strand transfer inhibitors (InSTI) for the treatment of HIV-1 infection: focus on weight changes, lipids, glucose and bone metabolism","volume":"21","author":"Savinelli","year":"2024","journal-title":"Curr HIV\/AIDS Rep"},{"key":"2025071504015707900_ofaf369-B31","doi-asserted-by":"crossref","first-page":"101116","DOI":"10.1016\/j.eclinm.2021.101116","article-title":"Stratifying the risk of NAFLD in patients with HIV under combination antiretroviral therapy (cART)","volume":"40","author":"Bischoff","year":"2021","journal-title":"EClinicalMedicine"},{"key":"2025071504015707900_ofaf369-B32","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1080\/25787489.2020.1848131","article-title":"Changes in central adipose tissue after switching to integrase inhibitors","volume":"21","author":"Debroy","year":"2020","journal-title":"HIV Res Clin Pract"},{"key":"2025071504015707900_ofaf369-B33","doi-asserted-by":"crossref","first-page":"2742","DOI":"10.1093\/jac\/dkz224","article-title":"Dual therapy combining raltegravir with etravirine maintains a high level of viral suppression over 96 weeks in long-term experienced HIV-infected individuals over 45 years on a PI-based regimen: results from the phase II ANRS 163 ETRAL study","volume":"74","author":"Katlama","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2025071504015707900_ofaf369-B34","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1097\/QAD.0000000000003289","article-title":"Relationship between weight gain and insulin resistance in people living with HIV switching to integrase strand transfer inhibitors\u2013based regimens","volume":"36","author":"Milic","year":"2022","journal-title":"AIDS"},{"key":"2025071504015707900_ofaf369-B35","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.3390\/cells10071687","article-title":"NNRTI and liver damage: evidence of their association and the mechanisms involved","volume":"10","author":"Benedicto","year":"2021","journal-title":"Cells"},{"key":"2025071504015707900_ofaf369-B36","doi-asserted-by":"crossref","first-page":"5592","DOI":"10.3390\/ijms23105592","article-title":"Antiretroviral therapy-induced dysregulation of gene expression and lipid metabolism in HIV+ patients: beneficial role of antioxidant phytochemicals","volume":"23","author":"Jim\u00e9nez-Osorio","year":"2022","journal-title":"Int J Mol Sci"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofaf369\/63571342\/ofaf369.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/12\/7\/ofaf369\/63571342\/ofaf369.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/12\/7\/ofaf369\/63571342\/ofaf369.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T08:02:05Z","timestamp":1752566525000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofaf369\/8173048"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,30]]},"references-count":36,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,6,30]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofaf369","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,7]]},"published":{"date-parts":[[2025,6,30]]},"article-number":"ofaf369"}}